Pre-IPO TenNor Therapeutics (Suzhou) Limited - The Pipelines and the Concerns

387 Views18 Sep 2025 08:55

China has vigorously restricted the use of antibiotics.TenNor's product won’t replace old ones completely due to higher price/difficulty of changing prescription habits.Valuation to be lower than peer

What is covered in the Full Insight:

Introduction to TenNor Therapeutics
The Chinese Antibiotics Market
Rifasutenizol (TNP-2198): A Core Product
Challenges and Regulatory Considerations
Valuation and Market Positioning

Xinyao (Criss) Wang

SUMMARY

(Sign Up to Access)

Try Now

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:

Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

SMARTKARMA PREVIEW PASS

By signing up, you agree to our
Terms of Use and Privacy Policy.

Already have an account? Sign In Now

Full Insight

(Paid Plans Only, 3-minute read)

Discussions

(Paid Plans Only)

Price Chart(Sign Up to Access)

Insight Stream